A novel <em>in vitro</em> prognostic model of bladder cancer based on urine-derived living tumor cells

Jiaqi Wang; Jiying Zhu; Junchi Hu; Ziruoyu Wang; Xiaobo Wang; Jianbo Pan; Yiwei Chu; Zengxia Li; Wei Jiang; Chunmin Liang; Jun Hou; Jianming Guo; Yongjun Dang; Shuai Jiang

doi:10.1016/j.gendis.2022.10.022

您当前的位置：

首页 >

文章列表页 >

A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells

Full-length article | 更新时间：2024-02-04

- A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells
- Genes & Diseases Vol. 1, Issue 6, Pages: 2586-2596(2023)
- 作者机构：
  
  1. Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education and Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University,Shanghai,China,200032
  2. Department of Immunology, School of Basic Medical Sciences, Fudan University,Shanghai,China,200032
  3. Laboratory of Tumor Immunology, Department of Anatomy, Histology, and Embryology, School of Basic Medical Sciences, Fudan University,Shanghai,China,200032
  4. Center for Novel Target and Therapeutic Intervention, Chongqing Medical University,Chongqing,China,400016
  5. Department of Pathology, Zhongshan Hospital, Fudan University,Shanghai,China,200032
  6. Department of Urology, Zhongshan Hospital, Fudan University,Shanghai,China,200032
  7. Department of Urology, Zhongshan Hospital Wusong Branch, Fudan University,Shanghai,China,200940
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.10.022
  CLC：
- Published：2023，
  
  Published Online：1 November 2023，
扫描看全文
Jiaqi Wang, Jiying Zhu, Junchi Hu, et al. A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells. [J]. Genes & Diseases 1(6):2586-2596(2023)
DOI：

Jiaqi Wang, Jiying Zhu, Junchi Hu, et al. A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells. [J]. Genes & Diseases 1(6):2586-2596(2023) DOI： 10.1016/j.gendis.2022.10.022.

摘要

Abstract

Bladder cancer (BLCA) remains a difficult malignancy to manage because of its high recurrence

intense follow-up

and invasive diagnostic and treatment techniques. Immune checkpoint inhibitors (ICIs) have forged a new direction for the treatment of BLCA

but it is currently challenging to predict whether an individual patient will be sensitive to ICIs. We collected 43 urine/tumor samples from BLCA patients for primary bladder cancer cells (BCCs) culturing using our previously reported BCC culture platform. We used flow cytometry (FCM) to measure the expression levels of Programmed Death-Ligand 1 (PD-L1) on BCCs before and after interferon-gamma (IFN-γ) treatment and found that PD-L1 expression and the sensitivities to IFN-γ varied among patients. RNA-sequencing

western blotting

and programmed death-1 (PD-1) binding assays confirmed that the BCC FCM-based PD-L1 detection platform (BC-PD-L1) was reliable and was not hindered by the glycosylation of PD-L1. In the subsequent retrospective study

we found that IFN-γ-stimulated PD-L1 (sPD-L1) expression on BCCs detected by BC-PD-L1 could predict the prognosis of BLCA patients. Importantly

the prognostic value was similar or even better in urine-derived BC-PD-L1 (UBC-PD-L1). Transcriptome analysis showed that BCCs with high sPD-L1 tended to enrich genes associated with the collagen-containing extracellular matrix

cell–cell adhesion

and positive regulation of the immune system. In addition

the UBC-PD-L1 also exhibited predictive value for ICI response in BLCA patients. In conclusion

as a novel personalized urine-detection method

UBC-PD-L1 may provide a rapid

accurate

and non-invasive tool for monitoring tumor progression

predicting therapeutic responses

and helping improve BLCA clinical treatment in future.

关键词

Keywords

Bladder cancerImmune checkpoint inhibitorsPredictive modelPrimary cellsUrine

references

1 C. BerdikUnlocking bladder cancer Nature, 551 (7679) (2017), pp. S34-S35

2 E. Christensen, K. Birkenkamp-Demtröder, H. Sethi, et al.Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma J Clin Oncol, 37 (18) (2019), pp. 1547-1557

3 V.G. Patel, W.K. Oh, M.D. GalskyTreatment of muscle-invasive and advanced bladder cancer in 2020 CA A Cancer J Clin, 70 (5) (2020), pp. 404-423

4 L. Tran, J.F. Xiao, N. Agarwal, et al.Advances in bladder cancer biology and therapy Nat Rev Cancer, 21 (2) (2021), pp. 104-121

5 A.T. Lenis, P.M. Lec, K. Chamie, et al.Bladder cancer: a review JAMA, 324 (19) (2020), pp. 1980-1991

6 M. Ignatiadis, G.W. Sledge, S.S. JeffreyLiquid biopsy enters the clinic - implementation issues and future challenges Nat Rev Clin Oncol, 18 (5) (2021), pp. 297-312

7 P.S. Chauhan, K. Chen, R.K. Babbra, et al.Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study PLoS Med, 18 (8) (2021), Article e1003732

8 X. Chen, J. Zhang, W. Ruan, et al.Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer J Clin Invest, 130 (12) (2020), pp. 6278-6289

9 J.C. Dudley, J. Schroers-Martin, D.V. Lazzareschi, et al.Detection and surveillance of bladder cancer using urine tumor DNA Cancer Discov, 9 (4) (2019), pp. 500-509

10 F.J.P.V. Valenberg, A.M. Hiar, E. Wallace, et al.Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer Eur Urol, 75 (5) (2019), pp. 853-860

11 H. Bao, H. Bi, X. Zhang, et al.Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: a multicenter, clinical-based, observational study Gynecol Oncol, 159 (1) (2020), pp. 171-178

12 T. Lebret, G. Pignot, M. Colombel, et al.Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test BJU Int, 129 (3) (2022), pp. 356-363

13 S. Jiang, J. Wang, C. Yang, et al.Continuous culture of urine-derived bladder cancer cells for precision medicine Protein Cell, 10 (12) (2019), pp. 902-907

14 K. Saeed, V. Rahkama, S. Eldfors, et al.Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer Eur Urol, 71 (3) (2017), pp. 319-327

15 D. Kim, B. Langmead, S.L. SalzbergHISAT: a fast spliced aligner with low memory requirements Nat Methods, 12 (4) (2015), pp. 357-360

16 R.J.C. Kluin, K. Kemper, T. Kuilman, et al.XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data BMC Bioinf, 19 (1) (2018), p. 366

17 S. Kovaka, A.V. Zimin, G.M. Pertea, et al.Transcriptome assembly from long-read RNA-seq alignments with StringTie2 Genome Biol, 20 (1) (2019), p. 278

18 M.I. Love, W. Huber, S. AndersModerated estimation of fold change and dispersion for RNA-seq data with DESeq2 Genome Biol, 15 (12) (2014), p. 550

19 T. Wu, E. Hu, S. Xu, et al.clusterProfiler 4.0:a universal enrichment tool for interpreting omics data Innovation, 2 (3) (2021), Article 100141

20 L. Väremo, J. Nielsen, I. NookaewEnriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods Nucleic Acids Res, 41 (8) (2013), pp. 4378-4391

21 M. Mandai, J. Hamanishi, K. Abiko, et al.Dual faces of IFNγ in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity Clin Cancer Res, 22 (10) (2016), pp. 2329-2334

22 M.R. Zaidi, G. MerlinoThe two faces of interferon-γ in cancer Clin Cancer Res, 17 (19) (2011), pp. 6118-6124

23 T.R. CoxThe matrix in cancer Nat Rev Cancer, 21 (4) (2021), pp. 217-238

24 E.A. Pietilä, J. Gonzalez-Molina, L. Moyano-Galceran, et al.Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance Nat Commun, 12 (1) (2021), p. 3904

25 E. Reeves, E. JamesAntigen processing and immune regulation in the response to tumours Immunology, 150 (1) (2017), pp. 16-24

26 S.V. Lindskrog, F. Prip, P. Lamy, et al.An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer Nat Commun, 12 (1) (2021), p. 2301

27 A. Chen, G. Fu, Z. Xu, et al.Detection of urothelial bladder carcinoma via microfluidic immunoassay and single-cell DNA copy-number alteration analysis of captured urinary-exfoliated tumor cells Cancer Res, 78 (14) (2018), pp. 4073-4085

28 H. Husain, V.O. Melnikova, K. Kosco, et al.Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine Clin Cancer Res, 23 (16) (2017), pp. 4716-4723

29 Y. Lotan, P.C. Black, L. Caba, et al.Optimal trial design for studying urinary markers in bladder cancer: a collaborative review Eur Urol Oncol, 1 (3) (2018), pp. 223-230

30 D.L. Rimm, G. Han, J.M. Taube, et al.A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer JAMA Oncol, 3 (8) (2017), pp. 1051-1058

31 H.H. Lee, Y.N. Wang, W. Xia, et al.Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy Cancer Cell, 36 (2) (2019), pp. 168-178 e4

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology

Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/β-catenin pathways

A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)

Identification of new aptamer BC-3 targeting RPS7 from rapid screening for bladder carcinoma

The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer

Related Author

Li Wang

Feng Luo

Zihan Xu

Ling Ma

Miao He

Shuang Dai

Hui Yu

Yingying He

Related Institution

Department of Medical Oncology, Lung Cancer Center, West China Hospital, Sichuan University

Cardiovascular Department, Mianyang Central Hospital

Oncology Department, Deyang People's Hospital

Department of Rheumatology and Immunology, Deyang People's Hospital

Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University

⁰

A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells

DOI：10.1016/j.gendis.2022.10.022

摘要

Abstract

关键词

Keywords

references